Clik here to view.
Transition begins Phase 1 study of TT-301
Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has dosed the first patient with its TT-301 drug candidate in a Phase 1 clinical study. TT-301 has demonstrated efficacy in preclinical models of...
View ArticleClik here to view.
NeoStem completing enrollment in heart trial
NeoStem (NASDAQ:NBS) is on track to complete enrollment later this year in a Phase 2 clinical trial of a bone marrow-derived cell therapy to treat patients for acute myocardial infarction, with a data...
View ArticleClik here to view.
William Blair starts Adamas Pharma at outperform
William Blair has initiated coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and price target of $35. The stock closed at $20.01 on Friday. Adamas is focused on therapies...
View ArticleClik here to view.
Enrollment in Athersys stroke trial nears completion
Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke...
View ArticleClik here to view.
biOasis to file IND for HER2+ brain cancer treatment in 2016
biOasis (OTCQX:BIOAF; TSX-V:BTI) hopes to file an Investigational New Drug application with the FDA next year to begin human testing of its Transcend platform against HER2 positive brain tumors, which...
View Article
